Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven Stodtmann

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Parkinsonism & Related Disorders|March 26, 2022
Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunumMatthew Rosebraugh, Sven Stodtmann, Wei Liu, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 22, 2025
Exposure-Response Modeling of Monthly Migraine Days for Efficacy of Atogepant in Patients With Episodic or Chronic MigraineLouisa Schlachter, Denise Beck, Ramesh R Boinpally, et al.
Journal of Clinical Pharmacology|May 29, 2026
Population Pharmacokinetics and Exposure-Response Analyses for Ubrogepant Efficacy and Safety in the Acute Treatment of Migraine: Analysis of Phase 1-3 StudiesSven Stodtmann, Lucia Siovitz, Heiko Babel, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 16, 2023
Integrating machine learning with pharmacokinetic models: Benefits of scientific machine learning in adding neural networks components to existing PK modelsDiego Valderrama, Ana Victoria Ponce-Bobadilla, Sven Mensing, et al.
Physical Chemistry Chemical Physics : PCCP|August 13, 2015
Parameter-free continuous drift-diffusion models of amorphous organic semiconductorsPascal Kordt, Sven Stodtmann, Alexander Badinski, et al.
Journal of Clinical Pharmacology|November 9, 2019
Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical TrialsAhmed Nader, Sven Stodtmann, Anna Friedel, et al.
Clinical Pharmacokinetics|November 12, 2025
Population Pharmacokinetics of Atogepant for the Prevention of MigraineLouisa Schlachter, Sven Stodtmann, Alexander Voelkner, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 9, 2025
Use of Model-Based Meta-Analysis to Inform the Design of Early Clinical Trials of Anti-Amyloid Beta Therapies in Alzheimer's DiseaseSagar S Bachhav, Ana Victoria Ponce-Bobadilla, Diana Clausznitzer, et al.
Clinical and Translational Science|October 28, 2024
Practical guide to SHAP analysis: Explaining supervised machine learning model predictions in drug developmentAna Victoria Ponce-Bobadilla, Vanessa Schmitt, Corinna S Maier, et al.
Clinical and Translational Science|August 5, 2025
Model-Informed Paradigm in Drug Development-An End-To-End Case Study From Upadacitinib DevelopmentSumit Bhatnagar, Sven Stodtmann, Yuli Qian, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Parkinsonism & Related Disorders|March 26, 2022
Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunumMatthew Rosebraugh, Sven Stodtmann, Wei Liu, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 22, 2025
Exposure-Response Modeling of Monthly Migraine Days for Efficacy of Atogepant in Patients With Episodic or Chronic MigraineLouisa Schlachter, Denise Beck, Ramesh R Boinpally, et al.
Journal of Clinical Pharmacology|May 29, 2026
Population Pharmacokinetics and Exposure-Response Analyses for Ubrogepant Efficacy and Safety in the Acute Treatment of Migraine: Analysis of Phase 1-3 StudiesSven Stodtmann, Lucia Siovitz, Heiko Babel, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 16, 2023
Integrating machine learning with pharmacokinetic models: Benefits of scientific machine learning in adding neural networks components to existing PK modelsDiego Valderrama, Ana Victoria Ponce-Bobadilla, Sven Mensing, et al.
Physical Chemistry Chemical Physics : PCCP|August 13, 2015
Parameter-free continuous drift-diffusion models of amorphous organic semiconductorsPascal Kordt, Sven Stodtmann, Alexander Badinski, et al.
Journal of Clinical Pharmacology|November 9, 2019
Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical TrialsAhmed Nader, Sven Stodtmann, Anna Friedel, et al.
Clinical Pharmacokinetics|November 12, 2025
Population Pharmacokinetics of Atogepant for the Prevention of MigraineLouisa Schlachter, Sven Stodtmann, Alexander Voelkner, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 9, 2025
Use of Model-Based Meta-Analysis to Inform the Design of Early Clinical Trials of Anti-Amyloid Beta Therapies in Alzheimer's DiseaseSagar S Bachhav, Ana Victoria Ponce-Bobadilla, Diana Clausznitzer, et al.
Clinical and Translational Science|October 28, 2024
Practical guide to SHAP analysis: Explaining supervised machine learning model predictions in drug developmentAna Victoria Ponce-Bobadilla, Vanessa Schmitt, Corinna S Maier, et al.
Clinical and Translational Science|August 5, 2025
Model-Informed Paradigm in Drug Development-An End-To-End Case Study From Upadacitinib DevelopmentSumit Bhatnagar, Sven Stodtmann, Yuli Qian, et al.
Pageof 3